A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs ANB 019 (Primary) ; ANB 019 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio
  • Most Recent Events

    • 29 May 2018 Results presented in an AnaptysBio media release.
    • 29 May 2018 According to an AnaptysBio media release, clinical data from this study was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018.
    • 08 May 2018 According to an AnaptysBio media release, 54 subjects are dosed with ANB019 and 18 are dosed with placebo.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top